The $913M bonanza: Arie Belldegrun and his top team at Kite show you how to make a really rich deal
When David Hung finished his deal to sell Medivation to Pfizer for $14 billion, he reaped a $355 million windfall as his reward as the master dealmaker in the industry. But if you think that’s a lot, you don’t know Arie Belldegrun.
Earlier this week, Kite Pharma laid out the rewards that fall to their executive team in light of the landmark $12 billion deal that they did with Gilead. And Belldegrun and his key team just illustrated how richly biotech can be rewarded when you make an historic advance in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
